Suggested remit - To appraise the clinical and cost effectiveness of siponimod within its marketing authorisation for treating secondary progressive multiple sclerosis in adults
Status In progress
Process STA 2018
ID number 1304

Provisional Schedule

Appraisal consultation: 1 25 June 2020 - 23 July 2020
Committee meeting: 2 09 September 2020
Expected publication 18 November 2020

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick


Companies sponsors Novartis (siponimod)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Association of British Neurologists
  Royal College of Physicians
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association


Comparator companies Novartis (interferon beta 1b)
  Bayer (interferon beta 1b) - (confidentiality agreement not signed, not participating)
  Biogen (dimethyl fumarate, interferon beta 1a)
  Merck (interferon beta 1a) (confidentiality agreement not signed, not participating)
  Mylan (glatiramer acetate) (confidentiality agreement not signed, not participating)
  Roche (ocrelizumab)
  Sanofi Genzyme (teriflunomide)
  Teva (glatiramer acetate(confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
17 June 2020 Siponimod for treating secondary progressive multiple sclerosis [ID1304] has now been rescheduled into the work programme . The topic webpage will be updated with the new timelines and expected publication date in due course.
02 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
12 March 2020 Committee meeting: 1
16 July 2019 Invitation to participate
16 July 2019 In progress. Appraisal has been referred to NICE.
20 November 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance